MedTrace Logo

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study

NCT00631228 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2012-08-14

No results posted yet for this study

Summary

XIENCE V® India is a prospective, open-label, multi-center, observational, single-arm study to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.

Conditions

Interventions

DEVICE

XIENCE V® Everolimus Eluting Coronary Stent

Drug eluting stent implantation stent in the treatment of coronary artery disease

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Ashok Seth, MD · Max Devki Devi Heart & Vascular Institute

  • Tejas Patel, MD · Krishna Heart Institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-04-30
Completion
2012-08-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00631228 on ClinicalTrials.gov